AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Policy quality-scores-3: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 5/6 · 31/10/2026
Moat—
Insufficient evidence for every rubric criterion; no category score is inferred.
structural advantage · 2/4 · Patents, proprietary know-how and named assay technologies establish differentiated assets rather than a purely generic offering. However, capable rivals also possess intellectual property and development resources. The passages do not establish exclusivity, superior customer outcomes or the revenue protected, supporting a mixed structural assessment.
durability · — · The catalog establishes existing intellectual property and ongoing technological change, but supplies no economically relevant patent lives, sustained competitive-share record or demonstrated persistence of customer switching barriers. These omissions prevent grading the duration of an economic advantage; technological risk alone does not establish realized erosion.
customer dependency · 2/4 · Actual software renewals, noncancelable subscriptions and customer use in development and manufacturing provide indirect evidence of recurring relationships and workflow relevance. Remaining performance obligations are immaterial, and neither migration costs nor renewal rates are disclosed. Dependency is therefore plausible and bounded rather than strongly demonstrated.
erosion resilience · 2/4 · Pricing actions partly offset 2024 gross-margin pressure, and fiscal 2025 continuing operating margin declined only slightly. Nevertheless, 2025 tariffs imposed a material cost and second-quarter 2026 operating income fell despite refunds. These actual outcomes support mixed resilience without proving competitive displacement or durable protection.
Pricing power50
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
realized pricing · 2/4 · Pricing actions partly offset gross-margin declines in both fiscal 2023 and fiscal 2024, establishing realized benefits. Their contribution is not quantified separately from productivity, mix or volume. The evidence supports some pricing effectiveness, but cannot establish sustained price realization or customer acceptance without demand trade-offs.
retention · 2/4 · Software contract renewals in the operating discussion demonstrate repeat demand, while noncancelable subscriptions and storage contracts provide limited commitment. This is indirect operating and contractual evidence rather than a measured retention rate. Renewal timing and immaterial remaining obligations limit conclusions about breadth, duration and renewal economics.
margin resilience · 2/4 · Fiscal 2025 GAAP continuing operating margin was 12.5%, versus 12.6% in 2024, despite tariff pressure. However, second-quarter 2026 operating income declined to $89 million from $91 million while including $16 million of tariff refunds. Resilience is mixed and cannot be attributed principally to pricing.
contractual freedom · 2/4 · The supplied Canadian sales terms permit adjustments for specifications, quantities and specified cost factors, demonstrating conditional pricing freedom. Their geographic and separately negotiated-quotation scope limits generalization. The disclosed need to price competitively further constrains economic discretion; company-wide repricing rights and customer termination provisions remain unknown.
Predictability72
5 consecutive published annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 50.00
- Revenue growth volatility (pp)
- 15.25
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 8.51
- observedAnnualPeriods
- 5.00
Financial strength31
Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or reported pretax profit plus reported gross interest expense. Reported EBIT is distinct from GAAP operating income and gross interest. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- debtFcfGrade
- 23.98
- netDebtEbitGrade
- 0.00
- interestCoverageGrade
- 26.08
- currentRatioGrade
- 74.60
- Debt / FCF (x)
- 6.32
- Net debt / operating income (x)
- 6.45
- Interest coverage (x)
- 3.87
- Current ratio (x)
- 1.68
Capital allocation75
Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or EBIT calculated from reported pretax profit plus reported gross interest expense; the issuer-reported EBIT is distinct from GAAP operating income and gross interest; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. ROIC remains undefined for nonpositive invested capital; the explicit asset-return alternative does not change the ROIC chart. Missing financial inputs alone never trigger an alternative. Does not establish acquisition quality or buyback timing.
- 3-year pre-tax operating return (%)
- 3.27
- 3-year average dilution (%)
- -2.59
- 3-year average SBC / revenue (%)
- 1.23
- cashConversionGrade
- 88.07
Management56
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · First-half 2026 continuing operating cash generation rose to $317.8 million, alongside $86.9 million of program repurchases. The completed acquisition required $72 million at closing plus up to $8 million contingent consideration through 2028. Cash generation supports capacity, but debt constraints and unproven investment returns warrant a mixed grade.
incentive alignment · 2/4 · Half of fiscal 2025 long-term incentives granted depend on financial performance. Actual ownership-guideline compliance as of February 17, 2026, clawbacks and hedging restrictions support alignment. A legacy single-trigger vesting provision weakens consistency. Granted award conditions do not establish realized vesting outcomes or exceptional shareholder alignment.
execution · 2/4 · Fiscal 2025 revenue and continuing operating income increased, and first-half 2026 continuing operating cash improved. These are indirect operating evidence of execution, without proving management causation. Second-quarter operating income fell despite tariff refunds, and first-half severance actions affected approximately 5% of the workforce, indicating uneven outcomes.
governance · 3/4 · Nine independent directors out of ten, an independent chair, majority voting and existing proxy access establish strong formal governance. Actual one-year director elections and approval of the 25% special-meeting threshold were confirmed after the annual meeting. Ownership and nomination thresholds constrain access; these arrangements do not demonstrate exceptional oversight outcomes.
Evidence
Intellectual Property
We own numerous United States and foreign patents and have patent applications pending in the United States and abroad.
2025 Form 10-K, filed 2026-02-24; Business—Intellectual Property · Filed 24/02/2026
In addition to our patent portfolio, we possess a wide array of unpatented proprietary technology and know-how.
2025 Form 10-K, filed 2026-02-24; Business—Intellectual Property · Filed 24/02/2026
◦A wide range of homogeneous biochemical and cell-based reagents using HTRF®, LANCE® Ultra™, DELFIA®, AlphaLISA®, AlphaLISA® SureFire® Ultra™, AlphaScreen®, and AlphaPlex® luminescence assay technologies that can be paired with our microplates, which cover a variety of applications.
2025 Form 10-K, filed 2026-02-24; Business—Life Sciences reagents · Filed 24/02/2026
We also license intellectual property rights to and from third parties, some of which bear royalties and are terminable in specified circumstances.
2025 Form 10-K, filed 2026-02-24; Business—Intellectual Property licensing · Filed 24/02/2026
Many of the businesses competing with us in these industries have significant financial and other resources to invest in new technologies, substantial intellectual property portfolios, substantial experience in new product development, regulatory expertise, manufacturing capabilities, and established distribution channels to deliver products to customers.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; Risk Factors—competing businesses' capabilities · Filed 11/08/2026
We sell many of our products in industries characterized by rapid technological change, frequent new product and service introductions, and evolving customer needs and industry standards.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; Risk Factors—technological change · Filed 11/08/2026
The decrease in Life Sciences segment revenue was driven by a decrease in instruments and reagents revenue due to pharmaceutical and biotechnology market headwinds, partially offset by an increase in software revenue from the timing of contract renewals and new orders.
2024 Form 10-K, filed 2025-02-25; MD&A—Life Sciences revenue and software contract renewals · Filed 25/02/2025
The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; revenue recognition—remaining performance obligations · Filed 11/08/2026
Many of our products are used by our customers to develop, test and manufacture their products.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; Risk Factors—customer use in development, testing and manufacturing · Filed 11/08/2026
The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; revenue recognition—materiality of remaining performance obligations · Filed 11/08/2026
The decrease in Life Sciences segment revenue was driven by a decrease in instruments revenue due to pharmaceutical and biotechnology market headwinds and a decrease in software revenue from the timing of contract renewals, partially offset by an increase in reagents revenue.
2023 Form 10-K, filed 2024-02-27; MD&A—Life Sciences revenue and renewal timing · Filed 27/02/2024
Our consolidated gross margin decreased 16 basis points in fiscal year 2024, as compared to fiscal year 2023, primarily due to an unfavorable shift in product mix and higher product costs, partially offset by pricing actions and productivity initiatives.
2024 Form 10-K, filed 2025-02-25; MD&A—gross-margin change and pricing actions · Filed 25/02/2025
Our consolidated gross margins decreased 411 basis points in fiscal year 2023, as compared to fiscal year 2022, primarily due to lower revenue from COVID-19 product offerings, and an unfavorable shift in product mix, partially offset by pricing actions.
2023 Form 10-K, filed 2024-02-27; MD&A—gross-margin change and pricing actions · Filed 27/02/2024
Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross margin by approximately $20 million, primarily affecting products manufactured in Europe for the U.S.
First-quarter 2026 Form 10-Q, filed 2026-05-12; Risk Factors—realized fiscal 2025 tariff costs · Filed 12/05/2026
GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related refunds), as compared to $91 million for the same period a year ago.
Second-quarter 2026 results release, filed 2026-08-04; GAAP continuing operating income, including tariff refunds · Filed 04/08/2026
GAAP operating profit margin from continuing operations for the year was 12.5% as a percentage of revenue, as compared to 12.6% in 2024.
Full-year 2025 results release, filed 2026-02-02; GAAP continuing operating margin · Filed 02/02/2026
Prices are subject to adjustment on account of specifications, quantities, raw materials, cost of production, shipment arrangements
Canadian sales terms, section 5; retrieved 2026-10-19, not a publication date; adjustment grounds subject to the supplied separately negotiated-quotation scope · Retrieved 19/10/2026
•price our products competitively, and manufacture and deliver our products in sufficient volumes and on time, and
Second-quarter 2026 Form 10-Q, filed 2026-08-11; Risk Factors—competitive pricing and delivery requirements · Filed 11/08/2026
Cash Flows
Operating Activities. Net cash provided by operating activities of our continuing operations was $317.8 million for the six months ended July 5, 2026, as compared to $268.4 million for the six months ended June 29, 2025, an increase of $49.4 million.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; MD&A—six-month continuing operating cash flows · Filed 11/08/2026
During the six months ended July 5, 2026, the Company repurchased 877,445 shares of common stock under the Repurchase Program for an aggregate cost of $86.9 million.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; Stock Repurchases—six-month program purchases · Filed 11/08/2026
13
Table of Contents
Note 3: Business Combinations
Acquisitions in fiscal year 2026
During the first quarter of fiscal year 2026, the Company completed its acquisition of Advanced Chemistry Development Inc.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; Note 3—completed first-quarter acquisition · Filed 11/08/2026
(“ACD/Labs”) for $72.0 million in cash paid at closing and up to $8.0 million in contingent consideration to be paid in cash based on the achievement of certain revenue metrics through 2028.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; Note 3—ACD/Labs cash consideration and contingent commitment through 2028 · Filed 11/08/2026
Risks Related to our Debt
We have a substantial amount of outstanding debt, which could impact our ability to obtain future financing and limit our ability to make other expenditures in the conduct of our business.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; Risk Factors—outstanding debt and financial flexibility · Filed 11/08/2026
Half (50%) of the long-term incentive compensation granted to our named executive officers in fiscal 2025 will vest based solely upon the achievement of financial performance metrics.
2026 proxy statement, filed 2026-03-16; Executive Compensation—fiscal 2025 long-term incentives granted · Filed 16/03/2026
As of February 17, 2026, all of our executive officers and directors were in compliance with the respective stock ownership guidelines.
2026 proxy statement, filed 2026-03-16; executive and director ownership-guideline compliance as of 2026-02-17 · Filed 16/03/2026
Our named executive officers are further subject to clawback policies, as well as restrictions on “short” sales and pledging and hedging of our securities.
2026 proxy statement, filed 2026-03-16; executive clawbacks and trading restrictions · Filed 16/03/2026
Mr. Goldberg’s employment agreement, which was executed before we changed our practice in 2010, also provides for the full vesting of all outstanding restricted stock, option awards, or similar equity awards in the event of a change in control.
2026 proxy statement, filed 2026-03-16; legacy change-in-control equity-vesting provision · Filed 16/03/2026
Revenue for the year was $2,856 million, as compared to $2,755 million in 2024.
Full-year 2025 results release, filed 2026-02-02; annual revenue comparison · Filed 02/02/2026
GAAP operating income from continuing operations for the year was $357 million, as compared to $347 million for 2024.
Full-year 2025 results release, filed 2026-02-02; annual GAAP continuing operating income comparison · Filed 02/02/2026
In the first and second quarters of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the Company’s workforce.
Second-quarter 2026 Form 10-Q, filed 2026-08-11; Note 4—first-half workforce reductions · Filed 11/08/2026
Audit; Compensation & Benefits
Yes
ii Revvity • 2026 Proxy Statement
Table of Contents
Corporate Governance Highlights
The following table summarizes our board structure and key elements of our corporate governance framework:
Size of Board
Ten
Number of Independent Directors
Nine
Independent Chair
Yes
Board Self-Evaluation
Annual
Review of Independence of Board
Annual
Independent Directors Meet Without Management Present
Yes
Structure of Board
Non-Classified
Voting Standard for Election of Directors in Uncontested Elections
Majority of Shares Cast
Wide Range of Backgrounds, Experiences and Skills
Yes
Corporate Governance Guidelines
Yes
Fiscal 2025 Business Highlights
We overcame a dynamic market environment throughout 2025, ultimately exceeding our financial targets provided at the beginning of the year.
2026 proxy statement, filed 2026-03-16; Corporate Governance Highlights—board structure and voting standard · Filed 16/03/2026
•
Our By-laws provide for proxy access, which permits shareholders, or a group of up to 20 shareholders, owning 3% or more of our outstanding shares of common stock continuously for at least three years, to nominate and include in our proxy materials nominees for director
82
Revvity • 2026 Proxy Statement
Table of Contents
constituting up to 20% of the board or two directors, whichever is greater, subject to the requirements set forth in our By-laws.
2026 proxy statement, filed 2026-03-16; existing proxy-access ownership, duration and nomination limits · Filed 16/03/2026
The shareholders elected each of the nominees to serve as a director for a term of one year.
Annual-meeting Form 8-K, filed 2026-05-01; actual director elections for one-year terms · Filed 01/05/2026
The proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm, the proposal to approve, by non-binding advisory vote, the Company’s executive compensation, and the proposal to amend the Company’s Amended and Restated By-laws to allow shareholders owning 25% of the Company’s common stock to call a special meeting of shareholders, which required that a majority of the shares of the Company’s common stock outstanding on the record date and entitled to vote be voted in favor of the proposal, were also approved.
Annual-meeting Form 8-K, filed 2026-05-01; approval of special-meeting bylaw amendment and other proposals · Filed 01/05/2026